Like a number of companies that went public during the pandemic, 23andMe has for months been trying to manage a terrible case of SPAC-itis, an inflammation that causes plunging stock values due to the business being, as one analyst put it, not “ready for prime time.” 23andMe, the DNA-testing powerhouse that once threw celebrity “spit parties,” went public in 2021 by merging with a special purpose acquisition company (SPAC) funded by billionaire Richard Branson. Briefly, it attained a $6... Read this story
